The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED (NCT02120079), a randomized phase 4 study. The primary outcome is IVCM for Density of Corneal Immune Dendritiform Cells.

2. Clinical Question

The trial also asked whether IVCM could be used to assess cellular responses and complement clinical findings noted during an eye examination. The registry describes the imaging as a way to measure immune cells associated with inflammation in the cornea. The posted primary endpoint is a density measure, expressed in cells/mm^2, rather than a reported change from baseline.

The primary comparison is between the Lotemax and artificial-tear groups at the stated 2 Weeks timeframe. In the posted results, the group means are 9.47 cells/mm^2 for Lotemax and 28.6 cells/mm^2 for artificial tears. The comparison is expressed as the artificial-tear mean minus the Lotemax mean. The interval and p-value are; they describe the posted comparison, not a conclusion about how either treatment should be used.

The registry describes the study as randomized, double-masked, and parallel-group. It does not report additional details about how masking was maintained, how randomization was conducted, or the clinical criteria used to enroll participants. Those omissions limit how fully the research question and its implementation can be assessed from the registry record alone.

3. Trial Design

This was a phase 4, randomized, double-masked, parallel-group study sponsored by Tufts Medical Center. The registry lists 37 participants as enrolled. Participants were assigned to Lotemax or Soothe Tired Eyes Lubricant Eye Drop (artificial tears). The study summary says both groups followed the same schedule and describes topical treatment over 6 weeks. The primary outcome, however, is reported at 2 Weeks; the registry record does not explain the relationship between that outcome timepoint and the overall treatment period.

The study had two related aims. One was to examine whether IVCM could assess corneal cellular responses and help confirm clinical findings. The other was to compare the two drops using IVCM measurements of immune cells, alongside ocular signs and symptoms. The registry lists IVCM as a diagnostic test as well as listing the two eye-drop interventions. It describes Lotemax as a steroid drop and artificial tears as a lubricating drop.

Primary outcome summaries include 17 participants in the Lotemax group and 20 in the artificial-tear group. The posted secondary summaries show outcome-specific participant counts, which are not identical for every measure. The registry does not state why the available numbers differ by outcome or provide a participant flow account in the record analyzed.

The record is marked completed. Its primary endpoint is a continuous measure summarized by a mean and standard deviation for each arm. The registry provides a between-group mean difference, an interval, and an unadjusted p-value. It does not list reported analyses in the relevant analysis fields. Details such as the original sample-size justification, the planned statistical model, interim analyses, analysis populations, and procedures for missing observations are not reported in the registry record. These details should not be inferred from the fact that the trial was randomized or from the posted summary statistics.

Thus, the design gives a randomized comparison of two assigned drops, but the posted result is best read as a comparison of the observed group summaries at the stated endpoint time. The registry record does not provide enough methodological detail to determine whether the reported comparison follows a particular adjusted or repeated-measures analysis.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Baseline

2 Weeks

6 Weeks

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as IVCM for Density of Corneal Immune Dendritiform Cells, measured over 2 Weeks.

The primary endpoint is the density of corneal immune dendritiform cells measured by IVCM, reported as a mean in cells/mm^2 at 2 Weeks. Dendritiform cells are the immune cells singled out in the endpoint description; the study summary frames their measurement as a way to assess the corneal immune response associated with DED-related inflammation. IVCM provides an imaging-based cellular measure rather than a symptom score or a clinician-assigned surface sign.

This endpoint was used to address the study’s stated interest in whether imaging could detect a cellular response and help assess the effect of the assigned drops. A quantitative density measure can summarize the observed cell burden in each group and permit a between-group comparison. In the posted results, the endpoint is summarized using a mean and standard deviation for each arm, with a mean difference for the comparison.

The distinction between an endpoint value and a change score matters. The registry names the density at 2 Weeks, but does not describe the primary result as change from baseline. A baseline-adjusted result, change-from-baseline estimate, or repeated-measures result is not reported in the registry record. The result therefore should be understood as the posted comparison at the specified timepoint, not as evidence about an unreported trajectory.

As a general statistical point, an imaging measure can add a biological dimension to clinical signs and patient-reported symptoms, but a measure’s statistical difference alone does not establish how well it captures a person’s experience or clinical status. The registry record does not report a validation analysis linking IVCM density to those other outcomes.

7. Results Posted in the Registry

• Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears): mean 28.60 versus 9.47 on control; difference 19.13 (95% CI 7.44 to 30.82), standardized effect d = 0.98; z-test p = 0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Ocular Signs: Corneal Epitheliopathy

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears): mean 3.18 versus 1.86 on control; difference 1.32 (95% CI -0.18 to 2.82), standardized effect d = 0.56; z-test p = 0.086.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears) and the control. The interval gives the range of effects that remain compatible with the data.

Ocular Signs: Conjunctival Epitheliopathy

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears): mean 4.50 versus 3.79 on control; difference 0.71 (95% CI -1.74 to 3.16), standardized effect d = 0.18; z-test p = 0.570.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears) and the control. The interval gives the range of effects that remain compatible with the data.

Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears): mean 33.16 versus 47.25 on control; difference -14.09 (95% CI -30.86 to 2.68), standardized effect d = -0.55; z-test p = 0.100.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears) and the control. The interval gives the range of effects that remain compatible with the data.

The secondary outcomes span ocular signs and symptoms: corneal epitheliopathy, conjunctival epitheliopathy, and the Ocular Surface Disease Index questionnaire. The registry also lists intraocular pressure among secondary outcome measures, although the detailed summaries discussed in the posted tables focus on the other measures. The secondary results add different kinds of context to the imaging-based primary endpoint, but they do not measure the same construct.

Across the displayed secondary comparisons, the estimated differences are less conclusive than the primary comparison: the reported intervals include zero. This means the posted estimates are compatible with differences in either direction as well as with no between-group difference, under the interval method used. The interval width and the outcome scale differ across measures, so they should not be compared as if they were all measuring a common quantity. Detailed values and directions are shown in the tables and are not repeated.

The secondary results do not negate or confirm the primary IVCM result. A cellular density measurement, an ocular sign score, and a symptom questionnaire capture distinct aspects of the study question. A pattern that does not line up perfectly across these measures is not, by itself, proof of contradiction. The registry does not report a formal analysis linking changes or values across the primary and secondary measures.

Unadjusted secondary results carry less weight when multiple outcomes are examined because the chance of at least one apparently unusual result can increase across a collection of tests. This is a general statistical concern, not a claim that any particular secondary finding is false. The registry record lists no reported secondary analyses and does not report a multiplicity adjustment, prespecified hierarchy, or primary-versus-secondary testing strategy. Accordingly, these outcomes are best treated as additional descriptive evidence rather than independent confirmatory conclusions.

The registry lists 12 secondary outcome measures, while the posted material includes repeated outcome categories and outcome-specific participant counts. The record does not explain every distinction among these entries or how missing observations were treated. Readers should use the outcome tables for the individual summaries and avoid assuming that the displayed secondary results constitute a complete adjusted analysis of all measures.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Ocular Signs: Corneal Epitheliopathy
• Ocular Signs: Corneal Epitheliopathy
• Ocular Signs: Conjunctival Epitheliopathy
• Ocular Signs: Conjunctival Epitheliopathy
• Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire
• Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire
• Ocular Signs: Intraocular Pressure (IOP) by Measure of Applanation Tonometry
• Ocular Signs: Intraocular Pressure (IOP) by Measure of Applanation Tonometry

9. Statistical Interpretation

10. Statistical Methods Explained

What kind of outcome is this?

The primary measure is continuous: it is a cell density expressed in cells/mm^2. The posted summary gives a mean and standard deviation in each arm, then compares the two means. A mean describes the average observed value in a group. A standard deviation describes how spread out observations are around that group’s mean. They serve different purposes: the mean locates the group summary, while the standard deviation describes within-group variability.

The registry labels the outcome as a mean and reports standard deviations. It does not provide individual participant data, a distribution plot, or a description of whether values were transformed. The statistical procedure used for the sponsor’s comparison is not reported in the registry record, so it would be inappropriate to name a specific test or model based only on the summary numbers.

What does the mean difference represent?

The reported contrast is the artificial-tear group mean minus the Lotemax group mean. A positive value therefore indicates that the artificial-tear mean was higher for this endpoint. The estimate is 19.13 cells/mm^2. This difference is in the endpoint’s original units, which helps retain a direct connection to the measured density. The estimate is a comparison of group averages, not a statement that every participant’s value differed by that amount.

As a general statistical explanation, an unadjusted difference compares the groups without accounting for other variables in the estimate. The registry does not report an adjusted primary analysis, so this page describes the posted comparison as recorded rather than implying that a particular covariate adjustment was applied.

How should the interval and p-value be read?

The reported interval for the primary mean difference runs from 7.439 to 30.82 cells/mm^2. In general, an interval estimate conveys uncertainty about a population quantity compatible with the data and the method used to calculate the interval. The registry record does not state the confidence level or the interval-construction method in the information analyzed. The interval’s endpoints are both above zero, indicating that the reported range of values for the difference is positive.

The unadjusted p-value is 0.001. As a general explanation, a p-value measures how unusual data at least as incompatible with a specified null model would be, if that model and the test assumptions held. It is not the probability that the null hypothesis is true, and it does not measure the size or clinical importance of a difference. Because the test procedure is not identified in the registry record, the p-value should be treated as the posted result, without attributing it to a particular test.

Why can variability affect interpretation?

The posted standard deviations differ between groups, with more variability in the artificial-tear group. As a general point, greater spread makes group averages less precisely estimated when other factors are held comparable. In a randomized study, observed variability can still be substantial, particularly when the number of participants contributing to an outcome is limited. The comparison interval reflects uncertainty in the estimated contrast; it is not simply a description of the range of individual observations.

Over-dispersion is a general issue in count outcomes when the observed variation exceeds what a chosen count model expects. It is not appropriate to assume that issue applies: the registry reports this endpoint as a continuous density summarized by a mean and standard deviation, and does not identify a count model. More generally, model choice should follow the recorded outcome and analysis plan, not be inferred from the biological nature of the measurement alone.

What do the planning illustrations assume?

The sample-size illustrations are calculations based on the observed effect, not the trial’s original design. The listed assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. In general, the illustration asks how many participants per arm would be needed under those specified assumptions to detect a chosen effect with a chosen probability of detection. It is not a reconstruction of the trial’s design process.

The registry does not report the trial’s own sample-size justification, original target enrollment rationale, or analysis plan. These are not posted by the planning table and cannot be recovered from the observed group summaries. General explanations of these methods do not imply that the sponsor used the same procedure for the original study.

Why does the distinction between planned and reported analysis matter?

A randomized allocation describes how treatment assignment was organized, but it does not specify how outcomes were analyzed. For example, a reported comparison could be adjusted for baseline values, account for repeated observations, or analyze only a defined population; none of these details should be assumed unless they are stated. The registry record does not report these analysis details. It also does not report the handling of missing data or whether there were interim analyses.

There are no reported analyses listed for the secondary results. Their displayed summaries and unadjusted p-values should therefore be read as the posted outcome comparisons, not as a complete account of a prespecified testing strategy. General statistical interpretation can clarify what means, intervals, and p-values convey, but cannot fill gaps in the registry’s account of the methods.

11. Confidence Intervals and Precision

The primary mean difference is 19.13 cells/mm^2, and its reported interval extends from 7.439 to 30.82. The width of an interval is one way to judge precision: a narrower interval indicates less uncertainty about the estimated difference under the method used, while a wider interval indicates more. Here, the entire reported interval is above zero, so the values covered by that interval point in the same direction as the estimated contrast. The registry record does not identify the confidence level or calculation method, so the interval should be described as reported rather than assigned a confidence level not stated in the record.

Precision is not the same as importance. An interval can be interpreted in relation to the scale of the endpoint, but the registry does not report a threshold for a clinically important difference in corneal cell density. It also does not report a validation analysis showing how a difference in IVCM density relates to clinical signs or symptoms. Statistical separation from zero therefore does not establish that the size of the contrast is meaningful to patients or clinicians.

The primary estimate is based on 17 participants in the Lotemax arm and 20 in the artificial-tear arm. The group standard deviations are 5.13 and 26.09, respectively. These summaries indicate that the observed values had different degrees of spread across the arms. With relatively small outcome groups and variability, the estimate should not be treated as exact; the reported interval is useful because it displays uncertainty around the difference rather than presenting the point estimate alone.

As a general statistical point, precision also depends on the design, analysis, and data quality, not only the number of participants. Since the registry does not describe missing-data handling, baseline adjustment, or the interval method, those factors cannot be evaluated. The posted interval is evidence about the reported comparison, not a guarantee that all sources of uncertainty have been captured.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size table and its companion curve are planning illustrations based on the observed effect, not a record of how the study was originally designed. For these continuous outcomes, the displayed figures are participants per arm, not total events. The assumptions listed for the illustrations are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The selected effect to detect is a stated fraction of the observed effect.

The 80% power column means the number of participants per arm estimated to give an 80% probability of detecting the chosen effect under those assumptions. The 90% power column uses a higher target probability of detection under the same stated framework. These are prospective planning quantities, not statements about what happened in this trial. The posted illustrations are not observed power.

Rows that plan for a smaller fraction of the observed effect require more participants per arm. This is a general feature of power calculations: if the difference to be detected is smaller, it is harder to distinguish from sampling variability, so a larger study is generally needed to achieve the same target power. The curve visualizes the planning relationship across the displayed effect assumptions; it does not add outcome evidence beyond the table.

The illustration uses the observed effect as its starting point, so its values depend on the effect estimate from this study. If the true effect in a future setting differs, the planning requirements may differ too. The registry does not report the original sample-size justification, the assumptions used by investigators before enrollment, or whether any planned reassessment occurred. Consequently, these calculations should not be used to infer the study’s original target, adequacy, or actual probability of detecting an effect.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = 19.130; pooled standard deviation σ = 19.533.
2. n = 2 × (1.96 + 0.842)² × 19.533² / 19.130² = 16.4, rounded up to 17 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- 19.13                      # observed difference in means
sigma <- 19.5332275878821                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(2120079)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 17 (80% power), 22 (90% power)
 75% of observed effect: n per arm = 30 (80% power), 39 (90% power)
 50% of observed effect: n per arm = 66 (80% power), 88 (90% power)
power.t.test: 17.4 
Simulated power at n = 17 per arm: 0.788 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when investigators evaluate more than one outcome, timepoint, group comparison, or analysis. As a general statistical principle, a collection of unadjusted tests can produce more opportunities for chance findings than a single prespecified test. This does not make each result invalid, but it affects how confidently secondary findings can be treated as confirmatory. The registry lists multiple secondary outcome measures and reports unadjusted p-values for the displayed secondary comparisons.

A multiplicity plan might specify which outcome is primary, how secondary hypotheses are ordered, or whether a statistical adjustment is used. Such a plan is not reported in the registry record. The record also does not describe whether the displayed analyses were selected from a larger set of planned analyses. It is therefore not possible to determine from the posted record how multiplicity was addressed, if at all. The primary endpoint remains the stated main outcome, but the lack of a reported testing strategy is relevant when interpreting the secondary findings.

Missing data are another important consideration. The primary summaries include 17 participants in the Lotemax group and 20 in the artificial-tear group; some secondary summaries have different group counts. The record does not explain why participant counts vary by outcome, whether observations were missing, or how missing values were handled. It does not report imputation, a complete-case approach, or sensitivity analyses. These procedures should not be inferred from the outcome counts alone.

The registry record also does not state the analysis population, such as whether the primary analysis followed all randomized participants or a subset. Randomized allocation is reported, but that fact alone does not establish which participants were included in each analysis or how deviations from assigned treatment were handled. No interim analyses or stopping rules are reported in the record analyzed.

These absences do not change the numerical summaries that are posted, but they limit assessment of the analysis process and robustness. A fuller interpretation would require the statistical analysis plan and information about outcome availability and participant inclusion. In their absence, conclusions should remain tied to the reported group summaries and should be cautious, especially for secondary comparisons.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event section reports zero serious adverse events in the Lotemax group among 17 participants at risk and zero in the artificial-tear group among 20 participants at risk. It also reports zero other adverse events in each group. The registry lists zero deaths in both groups, and no serious adverse-event terms are listed.

These figures describe the events recorded in the registry for the participants and period represented in that section. They do not establish that no events of any kind occurred outside the categories or reporting captured there. The registry record does not provide further detail about event definitions, collection procedures, timing, or follow-up completeness in the information analyzed.

As a general statistical point, observing no recorded events does not show that an event is impossible or that a treatment has no safety risks. The group sizes are limited, and the record does not provide an analysis of comparative safety. The figures should therefore be read as the posted counts, not as a broad safety conclusion or medical advice.

16. What the Result Does, and Does Not, Mean

The primary result answers a specific statistical question: how the observed mean corneal immune dendritiform cell density at 2 Weeks differed between the two randomized groups. The posted mean difference favors a higher observed density in the artificial-tear arm, and its reported interval lies above zero. This is the main quantitative finding in the registry record. It is not a direct measure of symptom relief, overall disease status, or a complete assessment of the treatment period.

The study summary describes IVCM as a method for assessing cellular response and potentially confirming clinical findings. The posted comparison is consistent with the possibility that IVCM can distinguish different group averages for this measure in this study. However, the registry record does not report a validation analysis, a diagnostic accuracy assessment, or a direct measure of agreement between IVCM and an eye examination. The primary result therefore cannot establish how reliably IVCM confirms clinical findings in general.

The difference also should not be translated into a claim that either intervention works or does not work. The record reports a between-group endpoint comparison, not a complete benefit-risk assessment. It does not report an established clinically meaningful threshold for this cellular measure, and it does not show that the observed difference corresponds to a meaningful change in symptoms or signs. Secondary outcomes add context, but their intervals include zero and their analyses are unadjusted.

The result should be interpreted within the trial’s scope: people enrolled in a single randomized, double-masked, parallel-group study, with an outcome reported at 2 Weeks. The registry lists 37 enrolled, but additional details about participant characteristics, eligibility, and the outcome analysis population are not reported in the registry record. That limits assessment of how broadly the result may apply.

In short, the posted data show a statistically distinct primary group comparison as reported, but they leave important questions open about clinical meaning, measurement validation, missing data, analysis methods, and generalizability. Those uncertainties are not resolved by the p-value or by the planning illustrations.

17. Why This Trial Matters Statistically

This trial is statistically notable because its primary question connects an imaging-based cellular measure with a randomized comparison of two topical eye-drop groups. The endpoint is not a conventional symptom score: it is corneal immune dendritiform cell density measured by IVCM. That makes the result relevant to a broader research question about whether quantitative imaging can contribute information about cellular responses in DED.

The record also illustrates why a point estimate should be read alongside its interval and the study context. The primary estimate is separated from zero by its reported interval, while the secondary comparisons are less precise relative to zero. Those patterns help distinguish the main posted signal from outcomes that remain uncertain. At the same time, the lack of a reported multiplicity plan, analysis population, and missing-data methods limits how strongly the secondary results can support further claims.

The sample-size illustrations offer a useful teaching example of planning conditional on an observed effect. Smaller effects require more participants under the stated assumptions, but those illustrations are not the original design rationale and do not show observed power. Keeping planned sample size separate from realized evidence is central to responsible interpretation.

Finally, this record shows the value and limits of registry reporting. The design, outcome summaries, intervals, p-values, and adverse-event counts give readers a starting point. The absence of detailed analysis methods and measurement-validation results means that readers should not infer procedures or clinical meaning that are not documented. This distinction is important whenever statistical evidence is presented alongside a novel measurement approach.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to what is documented for this study. The primary endpoint is reported at 2 Weeks, while the study summary describes a treatment period of 6 weeks. The registry record does not explain whether the primary timepoint was selected in advance, how other timepoints were analyzed, or how the 2 Weeks result relates to the full treatment period. The posted primary outcome also reports density at a timepoint, not a stated change from baseline.

The registry characterizes IVCM as a way to assess cellular response and clinical findings, but does not report a validation analysis or an association between the imaging result and clinical signs or symptoms. Thus, the posted outcome supports interpretation of the measured density comparison only; it cannot establish the accuracy or broader clinical utility of IVCM.

Outcome-specific participant counts vary in the posted summaries. The registry does not explain the reasons for these differences or report missing-data methods, an analysis population, or sensitivity analyses. Information on participant characteristics and detailed eligibility criteria is also not reported in the registry record, limiting assessment of how representative the enrolled group may be.

The record does not report the original sample-size justification, the full statistical analysis plan, the test or model used for the primary comparison, or a multiplicity strategy. It also does not report interim analyses. These omissions make it difficult to judge whether the displayed comparisons correspond to all planned analyses or whether other analytic choices could affect interpretation. The sample-size illustrations are based on the observed effect and stated assumptions, not a substitute for these missing design details.

Finally, the adverse-event counts are limited to the categories reported in the registry. Additional detail about event collection, follow-up, and definitions is not reported in the record analyzed. These documentation limits do not invalidate the posted numbers, but they constrain the conclusions that can reasonably be drawn from them.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED — NCT02120079.
• Registry record last updated 2024-06-26; status last verified 2024-06.
• Results first posted 2022-03-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry describes a completed phase 4 randomized, double-masked, parallel-group study sponsored by Tufts Medical Center. It enrolled 37 participants with dry eye disease to Lotemax or artificial tears. The primary outcome was corneal immune dendritiform cell density by IVCM at 2 Weeks.

The posted primary mean difference was 19.13 cells/mm^2 for artificial tears minus Lotemax, with a reported interval from 7.439 to 30.82 and an unadjusted p-value of 0.001. Secondary outcomes include ocular signs and symptoms; their posted comparisons are less conclusive and are unadjusted. The registry reports zero serious adverse events, other adverse events, and deaths in both groups.

Important details—including the original sample-size rationale, full analysis plan, multiplicity handling, and missing-data methods—are not reported in the registry record. The displayed sample-size figures are planning illustrations, not observed power.